The emerging application of next-generation sequencing in clinical care has facilitated the identification of low frequency somatic mutations and the testing of new therapies in solid tumors. However, little attention has been given to the relevance of non-synonymous germline variants which may be relevant to both prognostication and prediction of treatment response. The findings from our study highlight the utility of clinical sequencing panels across different cancer types for discovery of actionable somatic mutations and germline variants. Using this strategy we identified and functionally validated a KDR (VEGFR-2) germline variant (Q472H) that is present in one-third of melanoma patients. Our study addresses a critical area of translational oncology research: the identification of biomarkers that will allow development of personalized, genetic-based strategies to optimize patient selection and treatment outcomes. 
INTRODUCTION
Recently identified melanoma driver mutations have paved the way for rational development of effective targeted inhibitors that have increased survival rates for the metastatic patients whose tumors carry these specific mutations (1) (2) (3) (4) . Inhibition of the MAPK pathway in BRAF-mutated melanoma patients with BRAF and/or MEK inhibitors produces high response rates (1, 2, 5) .
However, approximately 30% of melanoma tumors lack activating mutations in BRAF or other somatic mutation drivers NRAS and KIT (6) (7) (8) , and are designated as wild-type (WT) melanoma.
While response rates to combination immune checkpoint blockade in BRAF WT tumors have been reported as high as 61% (9) , few effective treatment options are available for WT patients who do not respond to immunotherapy and/or experience unacceptable toxicity, eventually leading to the necessity to stop treatment. As next generation sequencing (NGS) technologies become increasingly economical (10, 11) , low frequency somatic driver mutations are being identified in multiple tumor types (12) (13) (14) , facilitating new clinical trial schemes, such as the "basket trial" in which patients are accrued for therapy according to a specific, targetable genetic alteration, independent of tumor histotype (15) .
When tumor-normal pairs are compared as a control to identify tumor-specific somatic mutations in NGS, non-synonymous germline variants can be identified through tumor-normal subtractive analysis (16, 17) . Recently, the Cancer Genome Atlas (TCGA) published a multilayer profiling of 333 cutaneous melanomas, revealing a catalog of potentially actionable somatic alterations.
However, common germline variants were excluded based on their presence in the "normal" sample (18) . In melanoma, germline variants have been described in high-(CDKN2A and CDK4), moderate-(MC1R), and low-penetrance susceptibility genes (19) . There are around 50 low-penetrance melanoma susceptibility genes that are relevant to pigmentation/nevus count, the anti-tumor immune response, DNA-repair, metabolism and vitamin D receptor polymorphisms.
Data from a recent melanoma GWAS (genome-wide association study) (20, 21) and evidence from our group (22, 23) demonstrate their impact on tumor progression and clinical outcome.
However, to our knowledge, no therapy targeting germline variants exists in melanoma.
In this study, we sought to examine the clinical utility of a targeted NGS approach to identify actionable somatic and germline variants with immediate relevance to the treatment of melanoma. We analyzed tumor and germline DNA from melanoma patients with a cancerassociated gene panel covering 2,800 COSMIC mutations within 50 known oncogenes and tumor suppressor genes. We identified potentially actionable somatic mutations in melanoma in WT tumors and characterized for the first time a pathogenic KDR germline variant (Q472H) in melanoma. Our data provide support for the concept of integrating germline DNA analyses to improve the personalized treatment of cancer patients.
MATERIAL AND METHODS

Patients
We studied a pilot cohort of 34 Stage III-IV and an independent cohort of 1,223 Stage I-IV melanoma patients. All patients were enrolled in the New-York University Interdisciplinary 
Biospecimens and cell lines
Tumor genomic DNA was extracted from macrodissected, formalin-fixed, paraffin-embedded (FFPE) melanoma tissue samples from the pilot cohort with the Qiagen QIAamp DNA FFPE Tissue Kit.
Germline genomic DNA was extracted from whole blood samples from melanoma patients with the Qiagen QIAamp DNA Blood Kit. Serum samples used for VEGF ELISA were collected from Stage III/IV melanoma patients before metastasectomy. Formalin-fixed paraffin-embedded (FFPE) tissues used for CD34 immunohistochemistry staining were obtained from metastatic melanoma samples. Primary established cell lines (WM 1575 and WM 3248) were purchased commercially from the Wistar Institute (Philadelphia, PA) where they were authenticated by short tandem repeat (STR) profiling (http://www.wistar.org/lab/meenhard-herlyn-dvmdsc/page/melanoma-cell-str-profiles) and used in our laboratory for no longer than six months following resuscitation. Primary melanoma patient-derived cell cultures were developed previously in our laboratory and were tested and authenticated against the original tumor specimens from which they were derived (24). 
Targeted Next-Generation Sequencing
Targeted next-generation sequencing data analysis
The sequencing data underwent a primary analysis using the Torrent Suite server. Optimized signal processing, base calling and sequence alignment was reviewed to assess the quality and accuracy of the sequencing runs. Detection of SNPs and indels from Ion-sequencing data was performed using Torrent Variant Caller software within the Torrent Suite. Secondary analysis (annotation) was performed by uploading VCF files into Ion-Reporter using the ion reporter uploader plugin. All variants identified were validated by Sanger sequencing.
Genotyping of KDR Q472H variant in validation cohort
1,223 germline DNA samples from the validation cohort were genotyped for the KDR Q472H variant using the MassARRAY iPLEX platform (Agena Bioscience, San Diego, CA, USA). The variant was in Hardy-Weinberg equilibrium (p=0.526).
Immunohistochemistry (IHC) and analysis of microvessel density (MVD)
IHC was performed on 26 formalin-fixed paraffin-embedded (FFPE) metastatic melanoma tumor samples. Tissues were evaluated for CD34 expression using a CD34-specific rabbit monoclonal antibody (1:500; Abcam, #ab81289). For each sample, the intra-tumoral region showing the highest MVD was selected and the density of microvessels were scored in a blinded-fashion in each sample at 20X magnification by an attending pathologist (Dr. Farbod Darvishian).
Quantification of serum VEGF levels
VEGF in cell line supernatants and patient sera was assessed by ELISA according to manufacturer's instructions (R&D Systems). All assays were performed in duplicate. 
Statistical methods
The association analysis of germline variants with melanoma survival was performed using univariate and multivariate Cox proportional hazards models under co-dominant model (2 degree freedom test) for both pilot and validation cohorts. Multivariate analyses were stratified by tumor stage and adjusted by clinicopathological covariates: age and thickness as continuous covariates; gender, ulceration status (present/absent), and anatomic site (axial/extremity) as dichotomous covariates; and histological type as categorical covariates. Kaplan-Meier plots were generated in 
RESULTS
WT melanomas exhibit clinically-relevant, actionable mutations
We used Ion Torrent NGS using a targeted panel of hotspot mutations from 50 genes implicated in different cancer types to (i) detect known actionable mutations in melanoma (eg. BRAF V600) and (ii) identify infrequent somatic mutations that occur in other tumor types and could be actionable in melanoma. Tumor and matched germline DNA from a pilot cohort of 34 patients were sequenced by Ion Torrent ( Figure S1 ), identifying a total of 66 somatic mutations in our pilot cohort (n=34) that were absent in matched germline DNA. The majority of the somatic mutations were missense mutations (60/66, 91%), 5/66 were nonsense mutations (8%), and only one frameshift deletion mutation was identified. The characteristic C>T transversions associated with the UVsignature of DNA damage were the most frequent changes observed (25) (Figure 1B ).
In the 36 tumors we analyzed from 34 patients (pilot cohort), we identified somatic mutations in BRAF, NRAS and KIT genes at frequencies that were consistent with those described previously (6-8) BRAF was mutated in 14/36 samples (39%), NRAS was mutated in 10/36 samples (28%), and KIT was mutated in 2/36 samples (6%) ( Figure 1C ). The majority of BRAF mutations were V600E (7/14; 50%) and V600K (3/14; 21%). Less common but previously characterized BRAF 
The germline KDR Q472H variant is found in one-third of melanoma patients
In the second phase of our analysis we examined 9 germline coding variants identified through normal-tumor subtractive analysis of the Ion Torrent sequencing of the 34 melanoma patients ( Figure 1D ). We elected to study a KDR (kinase insert domain receptor; VEGFR2) germline variant Q472H further as it has previously been shown to play a role in multiple cancer types, including lung adenocarcinoma (29) and demonstrated a high frequency in our patient cohort ( Figure 1D ) but remained unexamined in the context of melanoma. In an independent validation cohort of 1,223 germline DNA samples from melanoma patients (Table 1) Figure S5) .
The germline KDR Q472H variant is associated with a higher tumor microvessel density in melanoma
While we did not find a significant correlation between KDR Q472H and patient survival, other studies suggest that the impact of KDR on clinical outcome might depend on other KDR SNPs or the treatments patients received (30) (31) (32) (33) . Therefore, we sought to determine if KDR Q472H could impact the melanoma phenotype. KDR plays a crucial role in mediating angiogenic endothelial cell responses via the vascular endothelial growth factor (VEGF) pathway, and VEGF levels have been reported to correlate with tumor growth rate and microvessel density (MVD) (29, 34 heterozygous KDR Q472H patients, including patients from our pilot cohort). Our results showed nearly two-fold higher MVD in tumor samples from patients with KDR Q472H variant compared to KDR WT patients, where the mean MVD was 44.8 microvessels in tumors from patients carrying Q472H variant compared to 23.9 microvessels in tumors from KDR WT patients (Figure 2A ; p=0.01).
The germline KDR Q472H variant is associated with increased levels of serum VEGF in melanoma patients
The KDR Q472H variant is an alteration leading to increased VEGFR2 phosphorylation. In addition, the existence of a positive autocrine loop between VEGFR-2 and VEGF has been proposed to lead to higher levels of VEGF secretion that ultimately sustains enhanced angiogenesis (35, 36) . Therefore, we hypothesized that the KDR Q472H variant might stimulate an increase in VEGF secretion in melanoma patients and thus drive tumor angiogenesis. We first used a panel of four primary, melanoma patient-derived cell cultures (09-085, 09-241, 10-230, 11-161 (24)), and two established (WM 1575, WM 3248) melanoma cell lines, heterozygous carriers of the H472 variant or WT (Q472) KDR. All primary cultures were derived from patient tumors that were sequenced in our pilot cohort study. Analysis of VEGF levels by ELISA revealed a 29.7-fold increase in VEGF levels in tissue culture supernatants from KDR Q472H cell lines (09-085, 09-241 and 10-230; mean VEGF expression=968.5 pg/ml) compared to the supernatants from KDR WT cell lines (11-161, WM 1575 and WM 3248; mean VEGF expression=32.5 pg/ml) ( Figure 2B ). We then compared VEGF levels in sera (collected prior to surgical tumor resection) between KDR Q472H melanoma patients (n=36) and KDR WT patients (n=34) using ELISA. Our results confirmed that VEGF levels are significantly higher in sera from KDR Q472H patients (mean VEGF level=401.8 pg/ml) compared to sera from KDR WT patients (mean VEGF level=192.35 pg/ml) ( Figure 2B ; p=0.04).
Inhibition of KDR significantly decreases proliferation and invasion of melanoma cells carrying the KDR Q472H variant
We next assessed the proliferation of melanoma cells carrying KDR Q472H variant compared with KDR WT melanoma cells. While our results showed that proliferation rates were increased in melanoma cells with the KDR Q472H variant, this effect did not reach statistical significance In this study we performed targeted NGS to analyze both somatic and germline variants in 50 cancer-associated genes across 36 melanoma samples from 34 patients. We detected several lowfrequency novel actionable somatic mutations that warrant consideration for targeting through a "basket" trial scheme. Our data also identified a germline KDR Q472H variant in one third of melanoma patients that is associated with an angiogenic phenotype and which is selectively sensitive to targeted VEGFR2 inhibition.
We demonstrated that WT melanomas harbor somatic mutations that have been implicated in the progression of other cancer types and are potentially actionable, since inhibitors targeted against these mutations are in clinical development or have already been approved for treatment of other cancers (37, 38) . Our study identified nine such genes that were mutated in at least two different
samples: TP53, NOTCH, KRAS, SMAD4, HRAS, CDKN2A, CTNNB1, RB1 and SMARCB1.
Hence, we confirm that the targeted sequencing approach allows cancer-associated somatic mutations to be identified in melanoma tumor specimens, building on large-scale sequencing efforts in this and other tumor types (25, 39) . Observed at low frequencies that make individual melanoma specific clinical trials unfeasible, these data support the further development and application of the 'basket trial' concept: clinical trials of therapies targeted against a tumor's mutational status independent of the tumor histotype (eg. ClinicalTrials.gov Identifier:
NCT01219699 targeting PI3K).
Clinical sequencing of tumors to identify low frequency somatic driver mutations is likely to uncover incidental germline variants that might be relevant to cancer risk, prognostication, or treatment response. There have been extensive discussions of the utility and ethical considerations of reporting these results (40) . However, these discussions have mostly focused on findings that have clear medical value but that are secondary to the indication for ordering 
sequencing. Although the clinical sequencing practice currently limits the use of germline patient samples as a control to identify tumor-specific somatic mutations, the sequencing of "normal"-tumor pairs will have important clinical implications, by increasing the potential to identify impactful germline variants (22, 23) . First, the potential to unravel deleterious germline mutations known to be associated with a high risk of cancer (e.g. BRCA1/2, APC, p53) support the necessity to address the ethical and clinical impact of such incidental findings. Notably, in our study we detected 9 rare germline variants including 2 high-risk genes associated with cancer predisposition (TP53 and APC). The potential utility of common genetic variants in personalized medicine is emerging with the wealth of accumulated data from large population-based wholeexome sequencing efforts (41, 42) . Common germline variants have the potential for routine utilization and transformative clinical impact because of their distribution in a large proportion of patients. Second, the impact of germline variants in patients may affect the tumor microenvironment, which is considered essential for tumor development and progression, and may also impact the response to anti-tumor therapies and ultimately patient survival (43, 44) . We have recently shown that an interleukin-10 (IL-10) variant (rs3024493) has been significantly associated with melanoma overall survival and IL-10 secretion from CD4+ T cells, a finding that may have implications for the anti-tumor immune response (23) . In turn, this could modify determinants of tumor progression and therapy resistance, including angiogenesis, immunity and remodeling of the extracellular matrix. As such, far from being merely incidental findings, the germline variants captured on targeted sequencing panels are, in addition to somatic mutations, plausible candidates for better clinical and molecular stratification of melanoma patients, which would enable more effective personalized prognostication and treatment.
Research. We demonstrated that the KDR Q472H germline variant is associated with an angiogenic melanoma phenotype, characterized by significantly increased tumor vascular density and VEGF secretion. KDR is a VEGF receptor (VEGFR2) critical for physiological and tumor angiogenesis (45) , and multiple KDR genetic variants have been implicated in multiple tumor types (29, 30, 46) . Consistent with our findings, KDR has previously been correlated with increased endothelial cell angiogenesis via VEGF stimulation (47) , and KDR Q472H has been shown to mediate VEGFR2 phosphorylation and enhanced angiogenesis (29) . Our study extends these observations by showing that melanoma cells carrying the KDR Q472H variant not only secrete more VEGF but have a higher proliferative and invasive capacity. We demonstrate a dependence of KDR Q472H melanoma cell proliferation and invasion on KDR signaling, as melanoma cells that harbor KDR Q472H were sensitive to targeted inhibition of VEGFR2, an effect that was not (30, 33, 46) . These conflicting reports indicate that the precise clinical significance of individual KDR variants is likely to be specific to individual tumor types and to depend on the treatment regimen. Importantly, the size of the cohort being studied may play a crucial role in determining the relevance of KDR variants to clinical outcome, as small patient subsets used in many of these prior studies might significantly account for the variability of the observed associations with survival.
In summary, we have used a clinically-validated NGS assay to identify a novel germline variant, KDR Q472H, which promotes an angiogenic phenotype in melanoma. Further, we identified several actionable somatic mutations in BRAF/NRAS/KIT WT melanoma, a finding that has implications for the molecular stratification and treatment of these tumors. We propose that targeted sequencing approaches to identify clinically-relevant gene variants should not focus solely on somatic mutations, but instead should also include germline variants that might interact with somatic driver mutations to further promote tumor development and progression and could also represent novel therapeutic targets belonging to the tumor microenvironment.
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